The latest update is out from Alterity Therapeutics Ltd. ( (AU:ATH) ).
Alterity Therapeutics announced positive results from their ATH434 Phase 2 clinical trial, which will be presented at the American Academy of Neurology Annual Meeting. The trial showed significant improvements in patients with early-stage Multiple System Atrophy (MSA), with ATH434 demonstrating efficacy in reducing disability and improving motor performance. The use of wearable sensors in the study indicated increased activity levels in patients, and the drug showed potential in reducing iron accumulation in the brain, suggesting a promising impact on the treatment of MSA.
More about Alterity Therapeutics Ltd.
Alterity Therapeutics Ltd. is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases. Their primary product, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration, with a focus on treating Parkinson’s disease and Multiple System Atrophy (MSA). ATH434 has been granted Orphan Drug Designation by the U.S. FDA and the European Commission for the treatment of MSA.
Average Trading Volume: 100
Technical Sentiment Signal: Buy
Current Market Cap: $37.69M
For an in-depth examination of ATH stock, go to TipRanks’ Stock Analysis page.